Production (Stage)
Quest PharmaTech Inc.
QPT.V
TSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.21% | -47.52% | 47.67% | -56.08% | -64.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.06% | -25.32% | 55.85% | -71.26% | -41.85% |
| Operating Income | 3.06% | 25.32% | -55.85% | 71.26% | 41.85% |
| Income Before Tax | 177.03% | 18.67% | 104.54% | 507.05% | -704.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 177.03% | 18.67% | 104.54% | 507.05% | -704.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 177.03% | 18.67% | 104.54% | 507.05% | -704.56% |
| EBIT | 3.06% | 25.32% | -55.85% | 71.26% | 41.85% |
| EBITDA | -- | 25.51% | -55.33% | 71.25% | 42.14% |
| EPS Basic | 176.32% | 19.54% | 106.06% | 487.50% | -660.00% |
| Normalized Basic EPS | 100.00% | 11.11% | 66.67% | 280.00% | -633.33% |
| EPS Diluted | 176.32% | 19.54% | 106.06% | 487.50% | -660.00% |
| Normalized Diluted EPS | 100.00% | 11.11% | 66.67% | 280.00% | -633.33% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |